Solutionreach vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Patient engagement and communication platform for dental, medical, and optical practices with 400+ PMS integrations. Lehi UT; founded 2000;
About
Solutionreach is a Lehi, Utah-based patient engagement platform that has served dental, medical, optometry, and specialty healthcare practices with automated appointment reminders, patient messaging, satisfaction surveys, and online review management since 2000. As one of the earliest companies to build technology specifically for healthcare practice patient communication, Solutionreach has established a large installed base across independent practices and group practices in the United States. The platform integrates with over 400 practice management and EHR systems, triggering automated patient communication workflows based on appointment data, recall schedules, and clinical events—without requiring manual staff intervention for each individual patient interaction.\n\nSolutionreach's patient retention capabilities are central to its value proposition for healthcare practices. Research consistently shows that automated recall outreach significantly increases the percentage of patients who return for follow-up care and preventive appointments, and Solutionreach's multi-channel recall sequences—combining text, email, and phone reminders sent at configurable intervals—help practices reduce the attrition that erodes practice revenue over time. The platform's satisfaction survey module automatically collects patient feedback after appointments and routes positive responses to review sites while flagging negative feedback for internal service recovery, helping practices manage their online reputation systematically.\n\nSolutionreach has expanded its platform with online scheduling, telehealth integration, and digital patient intake forms to address the growing patient expectation for digital access to healthcare services. The company also offers practice benchmarking through aggregated data insights that allow practices to compare their recall rates, no-show rates, and online review volumes against peers in their specialty and geography. Solutionreach competes with Weave, Lighthouse 360, and RevenueWell in the dental and multi-specialty patient engagement market, differentiating on its depth of EHR and PMS integrations and its long track record with independent practice customers.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.